Targeted suppression of DDR2 prevents TA-MSCs from promoting the growth and metastasis of breast cancer cells, possibly due to the loss of the mesenchymal phenotype and downregulation of genes related to tumorigenesis in TA-MSCs [20]. The gene discussed is DDR2; the disease is breast cancer.